Zynerba Pharma (ZYNE) Reports Q1 Loss of $0.60/Share

Zynerba Pharma (NASDAQ: ZYNE) reported Q1 EPS of ($0.60), versus ($0.49) reported last year.

Financial Outlook

The company believes that the current cash position of $77.5 million is sufficient to develop five Phase 3-ready programs and, assuming support from the FDA to move forward, initiate at least one Phase 3 program and fund operations and capital requirements into 2019.

For earnings history and earnings-related data on Zynerba Pharma (ZYNE) click here.

You May Also Be Interested In

• Octave Intelligence plc (OCTV) Tops Q2 EPS by 4c ; Offers Guidance
• Avino Silver & Gold Mines (ASM) Misses Q2 EPS by 4c
• Sutro Biopharma Inc. (STRO) Misses Q2 EPS by 13c